In addition, there is little support for ACAT enzymes as a drug target for cardiovascular disease based on the lack of findings from SOAT1 and SOAT2 genome-wide association studies, and the absence of rare variants associated with relevant phenotypes. The gene discussed is SOAT1; the disease is cardiovascular disorder.